Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Net Margin (2018 - 2025)

TransMedics has reported Net Margin over the past 8 years, most recently at 11.56% for Q4 2025.

  • Quarterly results put Net Margin at 11.56% for Q4 2025, up 584.0% from a year ago — trailing twelve months through Dec 2025 was 17.47% (up 942.0% YoY), and the annual figure for FY2025 was 0.18%, down 787.0%.
  • Net Margin for Q4 2025 was 11.56% at TransMedics, down from 16.91% in the prior quarter.
  • Over the last five years, Net Margin for TMDX hit a ceiling of 370.43% in Q4 2021 and a floor of 239.46% in Q3 2021.
  • Median Net Margin over the past 5 years was 0.5% (2023), compared with a mean of 10.94%.
  • Biggest five-year swings in Net Margin: skyrocketed 45431bps in 2021 and later crashed -39265bps in 2022.
  • TransMedics' Net Margin stood at 370.43% in 2021, then crashed by -106bps to 22.22% in 2022, then skyrocketed by 113bps to 2.91% in 2023, then soared by 96bps to 5.72% in 2024, then soared by 102bps to 11.56% in 2025.
  • The last three reported values for Net Margin were 11.56% (Q4 2025), 16.91% (Q3 2025), and 22.17% (Q2 2025) per Business Quant data.